Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antihypertensive class labeling

Executive Summary

FDA's draft language for antihypertensive drug class labeling on cardiovascular outcomes claims will be considered by its Cardiovascular & Renal Drugs Advisory Committee on April 26. The committee proposed class labeling on improvement in cardiovascular outcomes from blood pressure reduction in June 2005 (1"The Pink Sheet" June 27, 2005, p. 8). The meeting, which will be held at the Hilton in Gaithersburg, Md. beginning at 8 a.m., will also address a meta-analysis of antihypertensive drug placebo-controlled trials. [Editor's note: To 2watch a webcastor order a video/DVD of this, or any other meeting, visit FDAAdvisoryCommittee.com.]...

You may also be interested in...



Hypertension DTC Ads Should Attribute Benefits To All Blood Pressure Drugs

Antihypertensive drug direct-to-consumer advertisements should include a statement that all drugs that lower blood pressure reduce risk of serious cardiovascular outcomes, members of FDA's Cardiovascular & Renal Drugs Advisory Committee said April 27

Antihypertensive Cardio Labeling Should Be Applied To New Classes – Cmte.

Class labeling for reduction of cardiovascular outcomes based on blood pressure lowering should be applied to new classes of antihypertensives, members of FDA's Cardiovascular & Renal Drugs Advisory Committee said

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel